Literature DB >> 7807192

High dose chemotherapy for the treatment of malignant brain tumors.

S H Petersdorf1, R B Livingston.   

Abstract

Conventional treatment of malignant high grade gliomas includes maximal resection followed by external beam radiotherapy. The addition of adjuvant chemotherapy has provided little improvement in the median duration of survival for these patients, particularly those patients with glioblastoma multiforme. The failure of conventional dose chemotherapy to improve the outcome of patients with high grade brain tumors has led several investigators to utilize high dose chemotherapy in order to overcome the limited benefit seen with conventional dose therapy which is due to intrinsic drug resistance as well as the impermeability of blood brain barrier. The majority of published studies utilizing this approach suggest that the addition of high dose chemotherapy with bone marrow transplant is of marginal benefit. However, most of these trials include small numbers of patients with advanced, refractory disease. A few trials have been reported utilizing high dose therapy in an adjuvant setting and the data from these studies are somewhat more promising. This review will analyze these studies and also discuss possible modifications of this approach in order to improve this aggressive treatment for patients who otherwise would have a dismal prognosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807192     DOI: 10.1007/bf01052725

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.

Authors:  E Sariban; K W Kohn; C Zlotogorski; G Laurent; M D'Incalci; R Day; B H Smith; P L Kornblith; L C Erickson
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

2.  High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.

Authors:  J E Mortimer; J S Hewlett; J Bay; R B Livingston
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 3.  Antineoplastic drug resistance in brain tumors.

Authors:  P C Phillips
Journal:  Neurol Clin       Date:  1991-05       Impact factor: 3.806

4.  High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.

Authors:  S N Wolff; G L Phillips; G P Herzig
Journal:  Cancer Treat Rep       Date:  1987-02

5.  Intravenous carboplatin for recurrent malignant glioma: a phase II study.

Authors:  W K Yung; L Mechtler; M J Gleason
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

Review 6.  High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience.

Authors:  H A Fine; K H Antman
Journal:  Bone Marrow Transplant       Date:  1992-10       Impact factor: 5.483

7.  High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.

Authors:  F H Hochberg; L M Parker; T Takvorian; G P Canellos; N T Zervas
Journal:  J Neurosurg       Date:  1981-04       Impact factor: 5.115

8.  Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.

Authors:  R S Leff; J M Thompson; M B Daly; D B Johnson; E A Harden; R J Mercier; G L Messerschmidt
Journal:  Cancer       Date:  1988-07-01       Impact factor: 6.860

Review 9.  Autologous bone marrow transplantation. Current status and future directions.

Authors:  B D Cheson; L Lacerna; B Leyland-Jones; G Sarosy; R E Wittes
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

10.  High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.

Authors:  J L Finlay; C August; R Packer; R Zimmerman; L Sutton; A Freid; L Rorke; E Bayever; N Kamani; E Kramer
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

View more
  10 in total

1.  Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

Authors:  Stephan Ulmer; Klara Spalek; Arya Nabavi; Susan Schultka; H Maximillian Mehdorn; Santosh Kesari; Lutz Dörner
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

Review 2.  Management of primary malignant brain tumours.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

3.  A murine model of targeted infusion for intracranial tumors.

Authors:  Minhyung Kim; Tara A Barone; Natalia Fedtsova; Anatoli Gleiberman; Chandler D Wilfong; Julie A Alosi; Robert J Plunkett; Andrei Gudkov; Joseph J Skitzki
Journal:  J Neurooncol       Date:  2015-09-16       Impact factor: 4.130

4.  Expression of annexin II in glioma cell lines and in brain tumor biopsies.

Authors:  S J Nygaard; H K Haugland; E K Kristoffersen; M Lund-Johansen; O D Laerum; O B Tysnes
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

5.  Incorporating BCNU wafers into malignant glioma treatment: European case studies.

Authors:  Anne Balossier; Lutz Dörner; Evelyne Emery; Oliver Heese; H Maximilian Mehdorn; Philippe Menei; Jagmohan Singh
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

6.  Loss of PTEN facilitates HIF-1-mediated gene expression.

Authors:  W Zundel; C Schindler; D Haas-Kogan; A Koong; F Kaper; E Chen; A R Gottschalk; H E Ryan; R S Johnson; A B Jefferson; D Stokoe; A J Giaccia
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

Review 7.  Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.

Authors:  M T Jennings; S Iyengar
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow.

Authors:  T F Cloughesy; Y P Gobin; K L Black; F Viñuela; F Taft; B Kadkhoda; F Kabbinavar
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

Review 9.  Pharmacokinetics of the carmustine implant.

Authors:  Alison B Fleming; W Mark Saltzman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.

Authors:  C Urban; M Benesch; B Pakisch; H Lackner; R Kerbl; W Schwinger; R Oberbauer
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.